Dr Reddy Share Price: DRREDDY operates within the Healthcare sector, specifically in the Drug Manufacturers – Specialty & Generic industries. Listed on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE), Dr. Reddy’s Laboratories Ltd has a significant presence in the Indian stock market.
In this detailed analysis, we will explore DRREDDY’s share price targets for 2024, 2025, 2026, and beyond, up to 2030. To forecast these long-term targets, we will employ various technical analysis methods.
To predict DRREDDY’s share prices up to 2030, we will use a machine learning model that bases its forecasts on historical performance. Over the years, Dr. Reddy’s Laboratories has demonstrated diverse trends.
This section will discuss DRREDDY’s current market position, its growth trajectory, financials and fundamentals of its price performance leading up to 2030.
Dr Reddy’s Laboratories Company Overview
| Company Name | Dr Reddy’s Laboratories Limited |
| Founded | 1984 |
| Headquarters | Hyderabad, Telangana |
| Industry | Pharmaceuticals |
| Chairman | Kallam Satish Reddy |
| Stock Exchange Listing | NYSE, NSE & BSE |
| Official Website | drreddys.com |
Dr Reddy’s Laboratories Fundamental Analysis
| Metric | Value |
|---|---|
| Market Cap | ₹1,11,800.29 Cr. |
| ROE | 19.54% |
| ROCE | 25.52% |
| P/E | 23.25 |
| P/B | 4.15 |
| Div. Yield | 0.6% |
| Book Value | ₹322.47 |
| Face Value | ₹1 |
| EPS (TTM) | ₹57.64 |
| 52 Week High | ₹1,421.49 |
| 52 Week Low | ₹1,104.13 |
Also Read: Inox Wind Share Price Target
Dr Reddy’s Laboratories Financials
Income Statement
| (INR) | 2024 | Y/Y change |
|---|---|---|
| Revenue | 279.16B | 13.54% |
| Operating expense | 98.30B | 14.40% |
| Net income | 55.68B | 23.56% |
| Net profit margin | 19.95 | 8.84% |
| Earnings per share | 66.92 | 22.10% |
| EBITDA | 79.01B | 21.23% |
| Effective tax rate | 22.52% | — |
Balance Sheet
| (INR) | 2024 | Y/Y change |
|---|---|---|
| Cash and short-term investments | 81.47B | 31.83% |
| Total assets | 387.52B | 20.40% |
| Total liabilities | 106.97B | 17.72% |
| Total equity | 280.55B | — |
| Shares outstanding | 832.64M | — |
| Price to book | 3.99 | — |
| Return on assets | 11.51% | — |
| Return on capital | 14.98% | — |
Cash Flow
| (INR) | 2024 | Y/Y change |
|---|---|---|
| Net income | 55.68B | 23.56% |
| Cash from operations | 45.43B | -22.83% |
| Cash from investing | -40.28B | 2.63% |
| Cash from financing | -3.76B | 85.99% |
| Net change in cash | 1.33B | 114.64% |
| Free cash flow | 12.23B | -58.79% |
Also Read: HAL Share Price Target
Dr Reddy Share Price Target From 2024 to 2030
| Year | Target Price |
|---|---|
| Dr Reddy Share Price Target 2024 | ₹1,367 |
| Dr Reddy Share Price Target 2025 | ₹1,504 |
| Dr Reddy Share Price Target 2026 | ₹1,738 |
| Dr Reddy Share Price Target 2027 | ₹1,986 |
| Dr Reddy Share Price Target 2028 | ₹2,384 |
| Dr Reddy Share Price Target 2029 | ₹2,756 |
| Dr Reddy Share Price Target 2030 | ₹3,227 |
Dr Reddy’s Laboratories Shareholding Pattern
- Retail & Other: 10.13%
- Promoters: 26.64%
- Foreign Institutions: 41.75%
- Mutual Funds: 10.86%
- Other Domestic Institutions: 10.61%
Also Read: Aban Offshore Share Price Target
Dr Reddy’s Laboratories Competitors/Peer Companies
- Sun Pharmaceutical Industries Ltd
- Cipla Ltd
- Mankind Pharma Ltd
- Zydus Lifesciences Ltd
- Lupin Ltd
- Aurobindo Pharma Ltd
- Alkem Laboratories Ltd
- Glenmark Pharmaceuticals Ltd
- IPCA Laboratories Ltd
- Alembic Pharmaceuticals Ltd
Also Read: Shalimar Production Share Price Target
To connect with us, click on any of the given social media buttons.
FAQs
-
What is the Dr Reddy Target Price in 2025?
1,504 INR.
-
What is the Dr Reddy Target Price in 2026?
1,738 INR.
-
What is the Dr Reddy Target Price in 2027?
1,986 INR.
-
What is the Dr Reddy Target Price in 2029?
2,756 INR.
-
What is the Dr Reddy Target Price in 2030?
3,227 INR.
Disclaimer: The information in this blog is for educational purposes only, and the targets mentioned in it are given as suggestions by market analysts. Therefore, before investing your money in any company, it is mandatory to get complete information about the company and consult your financial advisor.
